[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported a transaction dated 09/30/2025 in which 154 shares were acquired following vesting of restricted stock units. The Form 4 shows the acquisition price as $0, reflecting conversion of vested RSUs into common stock. After the transaction, the filing reports 18,282 shares of common stock beneficially owned by Mr. Krognes and 1,389 RSU-linked derivative shares reported as beneficially owned. The RSU award was originally granted on 08/09/2022 and vested 25% on 06/30/2023, with the remaining 75% vesting in substantially equal monthly installments over the following three years. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Krognes on 10/02/2025.

Positive

• 154 RSU shares vested and converted to common stock on 09/30/2025
• Director Steve E. Krognes increased direct ownership to 18,282 common shares
• RSU vesting follows the disclosed schedule from the 08/09/2022 grant, showing predictable compensation timing

Negative

• None.

Insights

Corporate Governance Expert

Insider vesting shows director ownership alignment with company equity.

The report documents a director-level vesting event of 154 RSU-derived shares on 09/30/2025, leaving the director with 18,282 common shares beneficially owned. Director vesting events are routine compensation mechanics; here they increase the director's direct equity stake without cash outlay, as the acquisition price is reported as $0.

This filing is procedural and does not disclose any sale or purchase in the public market or any change in board composition.

Compensation Analyst

Vesting follows a multi-year RSU schedule granted in 2022.

The RSU award was granted on 08/09/2022 with an initial 25% vesting on 06/30/2023 and the remaining 75% vesting monthly over three years. The 154 shares reported reflect a scheduled vesting installment converting to common stock at $0, consistent with restricted-unit settlement rather than a market purchase.

The filing confirms continuing periodic equity compensation rather than an extraordinary grant or accelerated acceleration event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		M		154	A	$0	18,282	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/30/2025		M			154	(1)	(2)	Common Stock	154	$0	1,389	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Guardant Health director Steve Krognes report on Form 4 (GH)?

The Form 4 reports that 154 shares were acquired on 09/30/2025 following vesting of restricted stock units; the reported acquisition price is $0.

How many total shares does Steve Krognes beneficially own after the reported transaction?

The filing reports 18,282 shares of common stock beneficially owned following the transaction.

When was the RSU grant that produced the vested shares originally made?

The RSU award was granted on 08/09/2022 and vested 25% on 06/30/2023, with the remainder vesting monthly over three years.

Did the Form 4 disclose any sale of shares by the reporting person?

No. The Form 4 discloses an acquisition via RSU vesting and conversion; it does not report any dispositions or market sales.

Who signed the Form 4 and when was it signed?

The Form 4 is signed by John Saia, as attorney-in-fact for Steve Krognes, on 10/02/2025.